<DOC>
	<DOCNO>NCT00411450</DOCNO>
	<brief_summary>The primary objective estimate effect human homolog Kirsten rat sarcoma-2 virus oncogene ( KRAS ) mutation status ( wild type versus mutant ) tumor tissue efficacy endpoints patient metastatic colorectal cancer ( mCRC ) receive second-line chemotherapy panitumumab fail first-line treatment .</brief_summary>
	<brief_title>Panitumumab Regimen Evaluation Colorectal Cancer Estimate Primary Response Treatment</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Diagnosis metastatic adenocarcinoma colon rectum Available paraffinembedded tumor tissue Failure first line treatment contain fluoropyrimidine oxaliplatin base chemotherapy bevacizumab mCRC Measurable disease Adequate hematologic , renal , hepatic metabolic function Radiotherapy ≤ 2 week prior Day 1 Cycle 1 Unresolved toxicity ( y ) prior anti cancer therapy , opinion investigator , precludes subject study enrollment Prior irinotecan therapy , anti epidermal growth factor receptor ( EGFr ) therapy , vaccine treatment mCRC CYP3A4 enzyme inducer , inhibitor , substrate ( eg , phenytoin , phenobarbital , carbamazepine , ketoconazole , rifampin , rifabutin , St. John 's Wort ) ≤ 2 week prior Day 1 Cycle 1 Infection require systemic anti infectives complete ≤ 2 week prior Day 1 Cycle 1 Clinically significant cardiovascular disease History interstitial lung disease ( eg , pneumonitis pulmonary fibrosis ) Pulmonary embolism , deep vein thrombosis , significant thromboembolic event ≤ 8 week prior Day 1 Cycle 1 Any significant bleeding ≤ 6 week prior Day 1 Cycle 1 , per investigator 's judgement Gastroduodenal ulcer ( ) determine endoscopy active uncontrolled gastrointestinal ulcer ≤ 4 week prior Day1 Cycle 1 Any comorbid disease condition could increase risk toxicity ( eg , dihydropyrimidine deficiency , significant ascites , pleural effusion ) Major surgery ( require general anesthesia ) , open biopsy , significant traumatic injury ≤ 4 week prior Day1 Cycle 1 . Subjects must recover surgery significant complication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>k-ras</keyword>
	<keyword>biomarker</keyword>
	<keyword>colorectal</keyword>
	<keyword>colon</keyword>
	<keyword>rectal</keyword>
	<keyword>FOLFOX</keyword>
	<keyword>FOLFIRI</keyword>
</DOC>